Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Anti-Ulcer drug shows promise for arthritis relief

NCT ID NCT05166304

Disease control Sponsor: October 6 University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether rebamipide, a drug normally used for stomach ulcers, can help control rheumatoid arthritis when added to standard methotrexate therapy. Sixty adults with active arthritis took either rebamipide or a placebo three times daily. Researchers measured joint pain, swelling, and disability to see if the drug improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rebamipide (an anti-ulcer drug) taken as 100 mg tablets three times daily
What this could lead to
If it works, this could offer a new, affordable add-on treatment to better control rheumatoid arthritis symptoms.
What could go wrong
This is a small, early-phase trial (Phase 1/2) with only 60 participants, so results may not apply broadly. Rebamipide is not a standard arthritis drug, and its benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

60 people

The number who actually took part.

Started

Jan 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients with active rheumatoid arthritis (disease activity score-28 joints: DAS-28 \> 3.2) based on the 2010 American College of Rheumatology (ACR) criteria16 were recruited. rheumatoid Patients who received the standard therapy (i.e. one or more conventional DMARDs) for at least three months. Exclusion Criteria: 1. History of biological DMARDS. 2. History of gastrointestinal surgery, GI ulceration,GI bleeding 3. Intolerance or allergy to rebamibide or methotrexate 4. Smoking or alcohol abuse 5. Any changes in using medication (changing the dosage or type of medicines) 6. Receive hormone replacement therapy, warfarin, and other anticoagulants

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • Minia University

    Minya, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.